Acquisitions (Tables)

6 Months Ended

Jun. 30, 2013

Business Acquisition [Line Items]

Business Acquisition, Pro Forma Information

	Three Months Ended June 30,					Six Months Ended June 30,
	2013		2012			2013		2012
	(in thousands, except per share amounts)
Net revenue	$	172,826	$	152,314		$	334,932	$	295,536
Net (loss) income	$	18,094	$	(65,162	)	$	5,531	$	(61,583	)
Basic earnings (loss) per common share	$	0.33	$	(1.21	)	$	0.10	$	(1.14	)
Diluted earnings (loss) per common share	$	0.30	$	(1.21	)	$	0.09	$	(1.14	)

Incline Therapeutics, Inc. [Member]

Business Acquisition [Line Items]

Schedule of Estimated Purchase Price

Total estimated purchase price is summarized as follows:

	(in thousands)
Upfront cash consideration	$	186,699
Fair value of contingent purchase price	87,200
Total preliminary estimated purchase price	$	273,899

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

Below is a summary which details the preliminary allocation of assets acquired and liabilities assumed as a result of this acquisition:

Assets Acquired:	(in thousands)
Cash and cash equivalents	$	1,563
Prepaid expenses and other current assets	624
Fixed assets, net	12,577
In-process research and development	250,000
Goodwill	99,956
Other assets	34
Total Assets	$	364,754
Liabilities Assumed:
Accrued expenses	1,413
Contingent purchase price	87,200
Deferred tax liabilities	89,442
Total Liabilities	178,055
Total cash price paid upon acquisition	$	186,699

Bristol-Myers Squibb [Member]

Business Acquisition [Line Items]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

Below is a summary which details the preliminary allocation of assets acquired as a result of this acquisition:

Assets Acquired:	(in thousands)
Product license	$	32,000
Option	62,000
Goodwill	21,000
Total Assets	$	115,000
Total cash price paid upon acquisition	$	115,000